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A B S T R A C T
Background: The evaluation process can be a lever to improve pathways of access to healthcare. The
objective of this article is to show how an evaluation strategy can both contribute to knowledge
development and have direct impacts on health services provision. We use the case of hepatitis C (HCV)
services organization to illustrate the use and the value of this evaluative approach.
Method: Inspired by empowerment evaluation, the transformative–participatory approach involved
overlapping phases of knowledge development and discussion with stakeholders. We conducted several
knowledge development activities to discern the needs of people with HCV, the resources available, and
the facilitators and impediments along the care pathway, starting from prevention and screening, all the
way through to treatment. Using an overlapping approach allowed us to regularly transfer acquired
knowledge back to the participants in the study settings and also to gather their impressions,
interpretations, and suggestions during periods of deliberation.
Results: The knowledge development activities made it possible to document the needs, resources, and
experiences of people affected by HCV. In the discussion sessions, viable solutions were identiﬁed to
improve health and healthcare access for people with HCV and to prioritize certain actions. This project
demonstrated that using the evaluation process can enable an instrumental, conceptual use of results
and, in fact, can have a transformative impact on services organization.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Evaluation and Program Planning
journal homepage: www.elsevier .com/ locat e/e valprogplan1. Introduction
The ﬁeld of evaluative research in health is where several trends
intersect. The ﬁrst of these is funding agencies’ intention to ensure
research is useful and to promote its use by the various settings
involved. This intention ﬁnds expression in the requirement to
transfer research-based knowledge into practice settings, with key
actors’ participation being targeted as a prerequisite for achieving
this objective (CHSRF, 2003, 2005; Denis & Lomas, 2003; Lavis,* Corresponding author at: CRHCLM, Université de Sherbrooke, Campus de
Longueuil, Bureau 200, C.P.11, Longueuil, Québec J4K-0A8, Canada.
E-mail address: astrid.brousselle@usherbrooke.ca (A. Brousselle).
http://dx.doi.org/10.1016/j.evalprogplan.2016.01.004
0149-7189/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unRoberston, Woodside, McLeod, & Abelson, 2003; Lomas, 2005). The
second is the recent trend of interventional research in health,
which aims to increase the impact of research results on
population health by no longer focusing on the analysis of
determinants of health, but rather on public health interventions
(Hawe & Potvin, 2009; Morabia & Costanza, 2012). The third is the
demonstrated synergy between the contextual characteristics of
the evaluation environment and the participatory approaches
adopted, which explains the use of evaluation results (Contan-
driopoulos & Brousselle, 2012).
These three trends, in complementary but different settings,
have led us to rethink the evaluative process, not—as has
traditionally been the case—to reach a judgment on the worth
and value of an intervention (Scriven, 1991), but rather to use theder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The objective of this article is to illustrate how a transformative–
participatory evaluation based on an empowerment evaluation
approach (Fetterman & Wandersman, 2005, 2007; Mertens, 2009;
Weaver & Cousins, 2004) can contribute to knowledge develop-
ment while, at the same time, having direct impacts on service
provision. Here we present the case of hepatitis C (HCV) services
organization to illustrate the use and the value of this evaluative
approach.
Hepatitis C, also known as the silent epidemic, is an infection
transmitted through blood-to-blood contact. Physicians have
access to treatments that can cure 50–80% of cases (MSSS,
2009), including recently introduced treatments that are even
more effective with fewer undesirable effects (Leclerc, Morissette,
Alary, Parent, & Blouin, 2014). However, even though Quebec has a
universal health insurance system, only 10% of persons diagnosed
with HCV received treatment in the period 1990–2004 (Allard &
Noël, 2006). Those most at risk of contracting HCV are intravenous
drug users (IDU). Even though the prevalence of infection is low in
the general population (1% in Quebec) (MSSS, 2009), 63% of IDUs
are infected (Leclerc et al., 2014; Noël et al., 2006), and more than
25% of IDUs contract HCV every year (MSSS, 2009). These persons
often present multiple issues related to mental health, the criminal
justice system, and co-occurring infections such as HIV, leading to
even greater social stigmatization (Chayer, Vieux, Bruneau, &
Jutras-Aswad, 2011; McCoy, Metsch, Chitwood, & Miles, 2001;
MSSS, 2009; Noel, Gagnon, & Cloutier, 2012; Popova, Rehm, &
Fisher, 2006). As such, they encounter signiﬁcant barriers to access
to healthcare (Butt, McGuinness, Buller-Taylor, & Mitchell, 2013;
Patten, 2006) and to HCV treatment in particular (Leclerc et al.,
2014). Those barriers to access to treatment for persons diagnosed
with HCV provided the impetus for this evaluative research
project.
First we describe the evaluative research approach we used. We
then present our ﬁndings and their impacts on knowledge
development, the results from stakeholder discussions, and theFig. 1. Evaluation steevaluation’s impacts on conceptual and instrumental use of
results.
2. Evaluation strategy and methodology
In this study we had two objectives: (1) to contribute to the
development of knowledge, and (2) to have an impact on the
organization of healthcare services for persons with HCV. Our aim
was to cover the complete care pathway, from prevention and
screening through to treatment. We designed a transformative–
participatory evaluation strategy (Weaver & Cousins, 2004)
inspired by empowerment evaluation (Fetterman & Wandersman,
2005), in such a way that the evaluation process itself could be
used as a lever to improve the situation being studied (Patton,
2012). The principle was to bring together stakeholders from
different settings, all of whom were involved in the issue, in order
to provide them with objective and credible information so that
they might come to a shared understanding of the problem and
develop solutions with as much consensus as possible. In that
sense, we put into practice two primary uses of the evaluation
process, as identiﬁed by Patton (2012, p. 144): enhancing shared
understanding and increasing participants’ engagement, sense of
ownership, and self-determination. In this process, the evaluators’
role involves not only developing knowledge, but also facilitating
and organizing discussions and deliberations.
The study was conducted over a two-year period (May 2011–
June 2013) in the Estrie region of Quebec, where access to hepatitis
C treatment for IDUs had been identiﬁed as problematic. We
formed a round Table of stakeholders selected based on their roles
in the care pathway of persons with HCV, along the continuum
ranging from HCV vulnerability all the way to treatment. Our
participants included street outreach workers, a person represent-
ing IDUs, community workers and professionals involved in
prevention and support for persons with HIV and STIs, profes-
sionals from the addiction rehabilitation center, representatives
from the soup kitchen, members of the local primary care centerps and activities.
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infectious diseases, and psychiatry. Average attendance at the
meetings was about 10 people, most of whom attended all the
meetings, with others joining in only once or twice. This project
received ethical approval from the various research committees
involved.
Our process involved overlapping phases of knowledge
construction and discussion with participants. Using an over-
lapping approach allowed us to regularly transfer acquired
knowledge back to the participants in the study settings and to
gather their impressions, interpretations, and suggestions during
periods of deliberation. As such, this was a participatory and
deliberative process in which objective and credible data were
used as a key means of structuring the discussions. Fig. 1 illustrates
the chronology and overlapping of the study phases.
We held ﬁve stakeholder meetings, each lasting two to three
hours. These meetings were recorded and transcribed verbatim so
that we could work from the transcripts. At the ﬁnal meeting, the
group developed a consensus on the most relevant and highest
priority solutions to improve the prevention–screening–treatment
pathway for people with HCV. First, going around the table, the
participants each put forward one or two problems they
considered high priority. Considering all the problems identiﬁed,
the participants each voted for three they saw as highest priority.
Then, for the two highest priority problems emerging from that
process, the group identiﬁed actionable solutions.
We conducted several knowledge development activities to
identify the needs of persons with HCV, the resources available,
and the facilitators and impediments along the care pathway
extending from prevention, through screening, all the way to
treatment. To discern the needs, we used two sources: (1) an
ongoing longitudinal survey of IDUs (SurvUDI) conducted byFig 2. Locations where sterile injectionQuebec’s public health institute, which provides sociodemo-
graphic and epidemiological data, as well as data on injection
and consumption practices, and (2) data from Quebec’s notiﬁable
diseases database (MADO) to develop a proﬁle of IDUs and persons
diagnosed as hepatitis C carriers in Estrie. To inventory the
available resources, we developed maps of the region’s resources.
We produced four maps each for the Estrie region and the city of
Sherbrooke, that region’s largest urban center, for a total of eight
maps, indicating: (1) locations where sterile injection supplies are
distributed for free (prevention) and the volume of orders (see
Figs. 2 and 3) (note that the maps do not show points of sale, such
as private pharmacies, which are important distribution points and
have extended opening hours); (2) hepatitis screening locations;
(3) locations providing treatment; and (4) resources providing
support services for IDUs and persons with HCV (lodging,
psychosocial support, etc.). We used a variety of data sources.
For syringe distribution locations, establishments designated as
centers for access to sterile injection supplies for the period April
2008–March 2011 were classiﬁed by level of activity in terms of
syringes distributed (low = 1–499 syringes, moderate = 500–999,
high = 1000 and over). To develop a proﬁle of the psychosocial
resources available, we consulted the websites of public establish-
ments and the directory of community organizations for the area.
We identiﬁed HCV screening sites in collaboration with the
regional Health and Social Services Agency, by means of the MADO
registry. Lastly, we identiﬁed the resources providing medical
treatment for HCV by looking at the missions of the region’s
various healthcare establishments and their admission criteria for
this clientele. The resulting maps were presented to our
participants, as well as to four focus groups of persons at different
points along the HCV pathway; they were then reﬁned based on
that feedback. supplies are distributed in Estrie.
Fig. 3. Locations where sterile injection supplies are distributed in Sherbrooke.
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pathways, we conducted focus groups. These were made up of: (1)
IDUs, to document their injection and syringe exchange practices
and their perceptions and use of resources in the region (two focus
groups); (2) persons diagnosed as HCV carriers but not in
treatment, to learn about their history with this disease, their
access to care and services, and barriers they encountered (one
focus group); and (3) persons diagnosed and treated for HCV, to
ﬁnd out about the conditions surrounding their access to
treatment and to document their care pathways (one focus group).
These focus group sessions were recorded and transcribed. To
determine whether we had reached saturation, we would have
needed to organize at least one more series of focus groups, but it
was not feasible to recruit participants for a second round (Krueger
& Casey, 2014). It was difﬁcult to recruit IDUs in the ﬁrst place, as
they were wary of exposure and mistrusted authority ﬁgures. In
the end, those we interviewed were not young people, but rather
people who had long experience with injection.
The project’s impact was documented through careful moni-
toring of changes attributable to the evaluation project, which was
accomplished by means of participant observations, by having a
key actor/partner in the team of co-investigators, and by surveying
the participants at the end of the project about their conceptual
and instrumental use of the study’s outputs.3. Results
The results are presented in three sections. We begin with the
empirical results of the project, after which we present the results
from discussions with partners. Lastly, we discuss conceptual and
instrumental uses of the ﬁndings of this evaluation project.
3.1. Development of knowledge
3.1.1. Needs
According to our data sources (SurvUDI and MADO), nearly 55%
of IDUs in the region studied were infected with HCV; 10.5% were
infected with both HCV and HIV. Men made up 83% of IDUs, yet the
women were proportionally more infected than the men (73% vs.
52%). The data revealed that 39% of IDUs between the ages of 25
and 39 years and 60% of IDUs aged 40 and over were infected with
HCV. Most lived in Sherbrooke, the regional capital, but the
numbers suggested considerable mobility, as 52% of IDUs had
moved within the previous six months. Also, 37% of those surveyed
were in prison. This percentage almost certainly overestimates the
real ratio of incarcerated to non-incarcerated IDUs, however, as
identifying and surveying IDUs in the community presents a
challenge for the SurvUDI survey recruitment process. Of all the
drugs consumed by injection, cocaine was the most frequent. For
35% of the IDUs, their ﬁrst injection occurred before the age of 20
years; 75% of IDUs injected in the presence of another person, 69%
with someone they knew, and most often they injected in their
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never exchanged needles with another IDU, but 61% reported that
they had occasionally used previously-used syringes.
With regard to IDUs’ use of services related to HCV, the data
showed that 97% had undergone at least one screening test in their
lifetime. One-quarter of them had been screened in a hospital, and
another quarter, in prison; 10% were screened by the clinical team
following the homeless, and 6% were screened at the local
community health center. Of the infected IDUs, 59.5% said they had
not consulted a physician about HCV in the previous six months,
and 82% said they had never taken any medication for this
infection.
These data reveal the magnitude of HCV infection among IDUs,
their great mobility, and the frequency of injection related to
cocaine use. These results raise questions regarding the availability
and accessibility of sufﬁciently large quantities of sterile injection
supplies and their availability in detention centers and near the
areas where IDUs reside. These data indicate good accessibility of
HCV screening services, but infrequent medical care and treatment
following diagnosis.
3.1.2. Resources
All the regional maps are presented in additional ﬁles (city
maps not included) (online Supplemental material). Here we
present only two of them, to illustrate the methodology used.
In Estrie, 150,000 free syringes are distributed annually. The
main locations where sterile injection supplies are available are
pharmacies and local community health centers (CLSCs). Of the 30
establishments listed, seven had a high distribution volume; these
were mostly located in Sherbrooke. Differences in distributionTable 1
Determinants of the health pathway of persons with hepatitis C.
Determinants Quotes
Prevention Availability of syringes “100 syringes . . . That’s 
Reception at the distribution locations “You’re never welcome w
know . . . .”
Poor knowledge about, or lack of interest in,
hepatitis C
“I know it because . . . fo
“I knew enough about it [h
had it: ‘It’s no big deal!’ I
Indifference toward the risk “And if I talk in terms of ‘m
like . . . To a certain poin
pfft, you don’t care.”
Injection practices “Like . . . I was stoned, I w
one that was contaminate
with it, you become blind
shoot up?’ So I put out m
Prison environment “We were 700 prisoners, a
probably used the same s
Screening Wanting a complete physical exam “And so around 20 years 
because I’m a very insecu
Getting tested for HIV “What worried me the mo
with a lot of partners, an
Partner’s insistence “At 45 years, my girlfrien
Worrisome test results “The nurse, when she gav
she didn’t actually say it w
and I was lucky, I actually
Information distributed on STIs and HIV “There were CLSC nurses w
initiative to have the bloo
Accompaniment “Because I was homeless, 
services, whatever. They 
Access to
treatment
Poor knowledge of the illness, feeling
healthy because symptom-free
“No symptoms, I didn’t fee
to be 90, either, you know
very much fun.”
Physician attitude at diagnosis “And that very same docto
hepatitis.”’
Fear of treatment “We used to hear people 
well, you were ﬂat on youvolume were due not only to prevalence of injection, but also to
differences in accessibility. In fact, certain high-volume distribu-
tion centers were located near other centers with low distribution
volumes, which underscores the importance of determinants of
accessibility. Only ﬁve of the 30 centers were actively engaged in
educating IDUs. Only two distribution points were open 24 h a day,
seven days a week, one of which was the hospital emergency room
(ER).
There was good geographic coverage of screening sites. The
urban centers carried out higher volumes of screening tests. HCV
screening was often done concurrently with HIV screening. When
the project started, HCV treatment was only available in the
region’s main urban center, at the hospital and the infectious
diseases outpatient clinic. As for psychosocial support, the maps
show good coverage regionally and considerable heterogeneity in
the types of services offered.
3.1.3. Facilitators and impediments in the care pathway
The in-depth analysis of the interviews is presented in another
article (Foley et al., submitted for publication). However, here we
present, in a table (Table 1), the determinants in the care pathway
of persons with HCV with regard to prevention, screening, and
access to treatment. We did not assume an HCV diagnosis was
routinely followed by treatment.
3.1.4. Cross-sectional analysis
In terms of prevention, cross-sectional analysis of these three
types of data conﬁrm the existence of a problem with regard to the
availability of syringes as a means of preventing HCV infection.
Most IDUs inject cocaine. During the period when they are usingnot much, 100 syringes, because you have to change syringes each time.”
hen you go to the ER to get syringes! Even the nurses look at you sideways, so, you
r me, in Estrie, hepatitis C, it was unknown to me. I took it lightly.”
epatitis C]. I knew a little about what it was like as an illness. I new that the person
 was stoned, so I didn’t care.”
e’, when I injected myself, I didn’t give a damn. I was in 10 feet over my head. It was
t, we’re chasing after our own death, bit by bit, you know? You know it, and . . .
as in a state of . . . a state of euphoria, in other words, of using cocaine. There was
d with HIV, and sometimes you manage to inject and sometimes you have trouble
. You have trouble ﬁnding your veins . . . So he said to me, ‘Do you want to . . .
y arm.”
nd out of those there were, I don’t know, 300–400 who were heroin addicts. So we
yringe to inject, I don’t know, 100 of us!”
ago, because, after all, I was using drugs, I said, just to have an idea, to be sure,
re person, I said, I’m going to be tested . . . I’d like to be tested for every disease.”
st, because I’m gay, was more HIV, which I wanted to check on because I’d had sex
d that’s when I found out that what I had was hepatitis C, and not HIV.”
d said: ‘Okay, now it’s the ﬁnger in the ass, the big test, go for the whole thing!”’
e me the results of my blood tests, she said my ATL enzymes were very high, and
as hepatitis, but I could see there was something. So then, I went into treatment,
 had the test, and I found out right away that I was infected.”
ho came and did a screening, talked with us about STIs and all that. So I took the
d tests.”
I was really like a homeless person, with no connections, no health services, social
just brought me there to . . . ”
l sick, you know . . . I didn’t know what I should do, and I wasn’t planning on living
 . . . I didn’t have the best life in the world, intravenous drug injection, that’s not
r even told me something once, he said: ‘You’ll die sooner from drinking than from
saying that it was like chemotherapy. And what we heard about chemo was that,
r back, your hair fell out, your teeth, your balls, the works, so! It was a huge battle.”
A. Brousselle et al. / Evaluation and Program Planning 55 (2016) 134–143 139cocaine, they inject many times and need a large number
of syringes (sometimes several hundred in a week), whereas our
data show a much more parsimonious distribution. Even though
there were two distribution points open at night, the IDUs seemed
to be aware only of one, the ER. Furthermore, the prison appeared,
in our focus groups, to be a setting that placed IDUs at particularly
high risk of reusing injection supplies. Nevertheless, the situation
reported by our respondents may not be the same in regional
prisons; this question needs further investigation.
The survey data, maps, and focus group results all conﬁrmed
good coverage in terms of hepatitis C screening.
Our empirical results conﬁrmed the problem of access to
treatment, which, from our data, appeared to be due to: (1) the fact
that there was only one treatment center, (2) professionals’
attitudes when announcing the diagnosis, and (3) the beliefs of
those diagnosed regarding the treatment’s side effects.
3.2. Results from stakeholder discussions
As our project advanced, we organized structured encounters
with stakeholders to discuss the results and enrich our analyses, as
well as to identify solutions for a more effective structuring of
service provision. The results of these discussions are presented
here, not meeting by meeting, but rather in thematic summaries of
the observations, from prevention to treatment. We also present
the results of the priority-setting exercises applied to the proposed
solutions for improving the prevention–screening–treatment
pathway for persons with HCV.
3.2.1. Prevention
The participants were surprised on several counts: the small
number of locations distributing free sterile injection supplies; the
number of syringes needed by the IDUs if they were to use new
supplies for each injection; and, as such, the considerable gap
between the number of syringes distributed and the actual needs
of IDUs, which was not apparent to them before our discussions.
They put forward several structural suggestions to optimize
preventive services, centered especially around the two key
concerns of accessibility and education.
1) The importance of making sterile injection supplies more
accessible, especially at night. Currently there are only two
distribution points open at night, and only one of them—the
ER—is widely known to IDUs. Participants said many distribu-
tion locations do not provide information on preventive
injection practices, are close-ﬁsted in terms of the number of
syringes they will give out, and insist on syringe exchange, as
opposed to simple distribution. However, since requiring the
return of used syringes is perceived as an obstacle to
accessibility, participants suggested that syringes be recuper-
ated without making this a condition for access to sterile
supplies. They stressed the importance of having a storefront
distribution site open 24 h every day. One participant, a street
worker, spoke about the effectiveness of multiplying agents:
actors in the community distribute injection supplies that are
then disseminated in large quantities by multiplying agents,
such as dealers or others who are in relatively close contact with
IDUs. However, such a system can only be set up if the worker is
able to establish a relationship of trust with those multiplying
agents, which is built up over time. Such a system also makes it
possible to recover used syringes. Police dismantling of
‘shooting galleries’ is an impediment to this type of distribution
strategy, however, as the sites where IDUs had been able to
congregate are closed, generating more mistrust of authority
and fears of getting caught.2) The importance of providing education and not just distributing
supplies. There appeared to be a consensus that distributing
sterile injection supplies will not have much of an impact if IDUs
are not also taught about safe injection practices. Yet many of
the current distribution sites did not devote any time to
education. The participants also insisted that, to be able to
convey certain educational messages, it is necessary to establish
human contact and a relationship of trust, and that this is
unlikely to occur in impersonal distribution sites such as
pharmacies and the ER, or if the IDU is in a state of withdrawal.
3.2.2. Screening
All the participants agreed it is not appropriate to suggest
screening to IDUs when they come to obtain syringes. Before
suggesting screening, workers need to establish a relationship of
trust and ﬁnd out about the person’s injection practices, which is
not easy to do while respecting the person’s privacy. The
participants also insisted on the need for post-screening interven-
tion, stressing the importance, when communicating the results, of
providing relevant information on the illness, means of prevention,
and existing treatments.
3.2.3. Treatment
When the project began, there was only one center that offered
treatment for HCV—the regional hospital. Our project contributed,
as a catalyst, to the creation of a second treatment site, at the
addiction rehabilitation center. This is a day center whose clinical
team consists of professionals trained in gastroenterology, nursing,
and psychoeducation. Within its ﬁrst year of operation, 25 persons
were seen in consultation and nine went into treatment. According
to the gastroenterologist, who also provides treatment at the
hospital, the rehabilitation center’s organization is ideal for
patients. The psychosocial support they receive is clearly
advantageous for treatment continuity. Thanks to this organiza-
tional model, the physician was able to accept in treatment some
less stable persons whom he would have hesitated to follow at the
hospital.
The eligibility criteria for treatment are quite restrictive. The
person must no longer be a regular user, and must be motivated
and sufﬁciently stable. For the time being, persons with co-
occurring HIV infection are not eligible, even though the
gastroenterologist stressed the importance of treating them;
otherwise these persons are at risk of dying of untreated hepatitis.
Organizing a multidisciplinary team appears to be one way of
reducing certain problems of access to treatment. Such a team,
made up of professionals in different organizations, could be
helpful in maintaining contact with the more unstable persons
who are not eligible for treatment, and might facilitate their access
to treatment when their living conditions become stabilized.
During treatment, a multidisciplinary team approach would lead
to better supervision and follow-up and increased patient
retention. The participants spoke about the need to establish
links with various resources and to develop clear pathways for
managing this clientele. They noted that the map of resources
showed there was already a great variety of psychosocial resources
in the region, and in large numbers, although some investigation
would be needed to ﬁnd out whether these resources were
prepared to get involved in following this clientele, and if so, under
what conditions. As such, there appears to be a need to identify and
provide training to organizations that would be willing to invest in
a continuum of services for persons with HVC.
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treatment pathway
3.2.4.1. High-priority problems. The problems identiﬁed by the
group are as follows, in order of priority based on voting: (1) no
identiﬁcation of available resources and lack of clarity about the
care pathway (need for formalized links, multidisciplinary
collaboration, support for persons affected, preparation for
treatment); (2) lack of availability in terms of the distribution of
sterile injection supplies (need for multiplying agents, distribution
resources, 24/7 coverage, supervised injection sites); (3) lack of
knowledge about HCV among IDUs and professionals; (4)
difﬁculties in accessing medical treatment for HCV (retention in
treatment, services performance, services organization,
geographic coverage); (5) non-existence of any sterile injection
supplies distribution program in the prison system (need for
creation of a treatment site); (6) lack of awareness among youth
(inadequate information on prevention, vulnerability of young
persons); (7) no identiﬁcation of measures to provide support
before, during, and after treatment; and 8) lack of pre- and post-
treatment counseling. The group identiﬁed actions to be
implemented for the two problems considered most important.Fig. 4. Evaluation project3.2.4.2. Priority actions to identify available resources and clarify the
patient pathway. Participants identiﬁed the need to build on
healthcare establishments’ and community resources’ willingness
to work together, in a complementary manner, to: (1) consolidate
the services network and the prevention–screening–treatment
pathway for HCV infection; (2) clarify the various participants’
respective roles and responsibilities; (3) make this pathway
known; and (4) obtain the support, including ﬁnancial support,
of the decision-making authorities to create and sustain the
relevant partnerships.
3.2.4.3. Priority actions to make sterile injection equipment more
available. Participants appraised the merits of setting up a shared
site where different service partners could take turns providing
coverage, not only to distribute sterile injection equipment, but
also to offer healthcare services, counseling, health education, and
psychosocial support, and to build on opportunities to establish
relationships with the IDUs.
Participants also recommended distributing syringes by the box
rather than singly and suggesting to IDUs that they pass them along
to their friends and acquaintances. This would be an easy and
inexpensive way to distribute a larger volume of syringes using
multiplying agents who already have signiﬁcant connections with
other IDUs. ﬁndings and impact.
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The aim of this project was to provide relevant and objective
information regarding the phenomenon of HCV in the Estrie region
of Quebec, so that the participants could develop a shared
understanding of the situation and might together identify some
avenues for solutions to improve services for persons with HCV.
This involved several types of research use: instrumental, when
research results have a tangible and programmatic inﬂuence on the
issue or program being studied; conceptual, when the study
inﬂuences the actors’ understanding of a phenomenon and their
conceptualization of it (Contandriopoulos, Brousselle, & Kêdoté,
2008; Greene, 1988; Weiss, 1977); and symbolic, when the results
serve to legitimize the pre-determined positions of certain groups
of actors (Beyer & Trice, 1982; Champagne, Lemieux-Charles, &
McGuire, 2004; Cousins & Whitmore, 1998; Greene, 1988; Preskill,
Zuckerman, & Matthews, 2003; Shadish, Cook, & Leviton, 1991).
Participatory evaluation has generally been seen as a means to
increase these three types of evaluation use (Turnbull, 1999).
In the context of this project, we are unable to assess the
symbolic use of the results. However, based on our observations
and on the participants’ perceptions of changes, we are able to
assess, to a certain extent, the conceptual and instrumental uses of
this project’s results. In Fig. 4, we summarize the main empirical
ﬁndings and link them with conceptual and instrumental uses.
3.3.1. Conceptual use
Conceptual use is a prerequisite to instrumental use. In a
situation where change is needed, it will not occur until
participants agree on the need for action, the solution to be
implemented, and the means to be mobilized. Contrary to non-
participative evaluation, in which ﬁndings are transmitted at a
given moment in time, in this project we dedicated speciﬁc times
to deliberation and exchange. The absence of disagreement, with,
at the end of the project, the identiﬁcation of priorities for action
are themselves records of conceptual use. We conducted partici-
pant observation activities during which we kept track of changes
in the various actors’ representations, undertakings, and commit-
ments. To supplement our observations, we developed a question-
naire that participants completed at their ﬁnal meeting. According
to the questionnaire, of the 10 attendees at that meeting, between
8 and 10 reported that, at the end of the project, they had more
knowledge about: the phenomenon of HCV in Estrie; the use of
injectable drugs; the realities for IDUs and persons with HCV;
unmet needs; difﬁculties related to prevention, screening, and
treatment; the roles of the different partners; and the solutions to
be implemented to improve the care pathways for persons with
HCV. Even though these results are self-reported, there appears to
have been a strong consensus that the project had an impact on the
participants’ knowledge and representations. The fact that the
discussions about solutions were not polarized is another
indication that the participants shared a common understanding
of the problems.
3.3.2. Instrumental use
In the ﬁeld of evaluation, instrumental use appears to be
relatively infrequent and most often occurs gradually and diffusely
(Contandriopoulos et al., 2008; Patton, 1988). Yet we were able to
observe modiﬁcations to the service offer that were directly
attributable to the evaluation project—in particular, the creation of
a day center for HCV treatment at the rehabilitation center. This
was a key spin-off of this project on healthcare services
accessibility. Other programmatic spin-offs might also be possible
if efforts could be invested in raising awareness among key actors
in the regional network. This latter dimension brings us to
consideration of the limitations of our approach.3.3.3. Limitations
The time frame of the evaluation project clearly limited the
implementation of real changes that could improve access to
health and healthcare for persons with HCV. The time frame
created a break in the conceptual-to-instrumental uses continuum.
The fact that this exercise was undertaken as part of a research
project gave this process a temporal frame that both mobilized the
actors and, at the same time, limited the time within which they
were able to pursue the objectives identiﬁed during the project. In
this respect, the main limitation of this project, the temporal limit,
was also its strength.
4. Discussion
Recently Contandriopoulos and Brousselle (2012) proposed a
new interpretation of the determinants of evaluation use. They
showed that the primary determinant is the ﬁt between the
premises of the evaluative theories/approaches used and the
study’s implementation context. In contexts where actors are
ready to invest resources, participative approaches are likely to
lead to an appropriation of results. Here we designed a
transformative–participatory approach inspired by empowerment
evaluation principles and methods. Research on empowerment
evaluation has shown that the empowerment evaluation approach
is regularly adapted to the evaluation context (Miller & Campbell,
2006), which is considered normal and desirable according to the
conceptors of this approach (Fetterman & Wandersman, 2007). The
evaluation process, in this case, was organized to allow periods of
discussion based on objective empirical data and to encourage the
various actors to take action. The fact that this study was
undertaken in a context that had been prepared and was receptive
to carrying out this evaluation project, that the actors were ready to
invest time and participate actively in the stakeholder meetings
(cost-sharing), and that they shared the perception that the current
situation of services for persons with HCV was inadequate (low
issue polarization)—all combined to position this study in what
Contandriopoulos and Brousselle have called “utilization para-
dise”. The good ﬁt between the evaluative approach adopted and
the evaluation context meant we could expect to observe a use of
the project’s results, to the extent that the participatory process
enabled actors to be mobilized and to integrate the knowledge
produced. Indeed, if evaluation use is explained by the ﬁt between
the evaluative strategy and contextual characteristics, then it is
contingent on the evaluation process that is designed and carried
out, as this article makes clear. This project illustrates how a
transformative evaluation project can be designed when the
approach selected is congruent with the evaluation context
characteristics. However, we consider that the participative
qualities, on their own, are insufﬁcient to explain the observed
evaluation use. We believe that using a deliberative process
structured around objective data is also a means of rallying the
actors and getting past any differences in perceptions. The relative
contribution of using objective data in deliberations, in relation to
the process itself of actors’ participation, warrants further
exploration in the ﬁeld of evaluation. This would help to identify
more clearly the relative effectiveness of participatory processes
and other components of the research strategy in contexts that are
conducive to the use of research results.
5. Conclusion
This evaluative project, while small in scope in terms of both
budget and time frame, perfectly illustrates the fact that strategic
use of the research process can effectively inﬂuence conceptual
and instrumental use of results. This article illustrates how a study
or evaluation can be organized in such a way that it becomes in
142 A. Brousselle et al. / Evaluation and Program Planning 55 (2016) 134–143itself interventional, as advocated by the PHIR movement (Hawe &
Potvin, 2009; Morabia & Costanza, 2012) and thereby contributes
not only to the development of knowledge, but also to improving
the problem situation. However, this project also raises other
fundamental questions: What determined the project’s effective-
ness in terms of results use? Was it the participatory processes
used, the use of objective data in the deliberations, or the context
that was conducive to using research results? Probably all three of
these components played a role, but the relative importance of
each remains to be explored. Various authors have analyzed the
determinants of research results use (see the synthesis of
Contandriopoulos, Lemire, Denis, & Tremblay, 2010) in relation
to evaluative theories (Contandriopoulos & Brousselle, 2012) or
have dissected participatory processes (Weaver & Cousins, 2004).
However, we still know very little about the mechanisms that, in
participatory processes and in use-conducive contexts, really
determine the effectiveness of research processes (Henri & Mark,
2003; Shulha & Cousins, 1997), and there is certainly a research
agenda to be found here on theories and practices in the ﬁeld of
evaluation.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
evalprogplan.2016.01.004.
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